Metropolitan Life Insurance Co. NY decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.2% during the first quarter, Holdings Channel reports. The institutional investor owned 113,110 shares of the medical instruments supplier’s stock after selling 1,322 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Becton, Dickinson and were worth $20,749,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. North Star Investment Management Corp. boosted its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Crestwood Advisors Group LLC purchased a new stake in shares of Becton, Dickinson and during the first quarter worth approximately $101,000. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. Financial Architects Inc boosted its stake in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the period. Finally, QCI Asset Management Inc. NY boosted its stake in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares during the period. 75.71% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 1.08% on Friday, hitting $200.36. The company had a trading volume of 1,251,199 shares. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm’s 50 day moving average price is $198.90 and its 200-day moving average price is $187.70. The stock has a market capitalization of $45.59 billion, a PE ratio of 58.02 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.35 EPS. Analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.46%. Becton, Dickinson and’s payout ratio is currently 83.43%.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/12/becton-dickinson-and-company-nysebdx-stake-reduced-by-metropolitan-life-insurance-co-ny.html.

BDX has been the subject of a number of research reports. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Cowen and Company reissued an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $195.79.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold a total of 44,019 shares of company stock worth $8,368,433 in the last 90 days. 1.40% of the stock is currently owned by company insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.